TY  - CONF
AU  - Palleis, Carla
AU  - Franzmeier, Nicolai
AU  - Gnoerich, Johannes
AU  - Jäck, Alexander
AU  - Bernhardt, Alexander M
AU  - Katzdobler, Sabrina
AU  - Fietzek, Urban
AU  - Weidinger, Endy
AU  - Frontzkowski, Lukas
AU  - Roemer-Cassiano, Sebastian
AU  - Zwergal, Andreas
AU  - Barthel, Henryk
AU  - Sabri, Osama
AU  - Levin, Johannes
AU  - Höglinger, Günter U
AU  - Brendel, Matthias
TI  - Clinical value of 18 F‐PI2620‐PET in the diagnostic workup of patients with suspected Progressive Supranuclear Palsy
JO  - Alzheimer's and dementia
VL  - 21
IS  - S2
SN  - 1552-5260
M1  - DZNE-2025-01449
SP  - e102121
PY  - 2025
AB  - Background:Progressive Supranuclear Palsy (PSP) is a rapidly progressing 4-repeat tauopathy, presenting with clinically heterogeneous phenotypes. Currently, diagnoses are based solely on clinical criteria but reliable diagnostic classification remains particularly challenging at early stages. 18F-PI-2620 tau-PET is an evolving neuroimaging biomarker to capture 4-repeat tau (4RT) deposits in vivo with clear diagnostic potential in research settings. To determine the added clinical value of 18F-PI-2620 tau-PET in the diagnostic workup of PSP, we evaluated whether 18F-PI-2620-assessed 4RT positivity (i.e. using the basal ganglia as a target readout) predicts subsequent increases of diagnostic certainty for PSP, indicative of 4RT pathology driving clinical progression.Method:We collected monocentric longitudinal data at the LMU Hospital in Munich, from a non-randomized prospective cohort study between October 2018 and December 2024. Data collection included pre-PET visits with routine clinical classification following the MDS criteria. In addition, we performed 18F-PI-2620 tau-PET with dichotomous visual read assessments of 4RT pathology by an expert reader and collected clinical follow-up data or autopsy information.Results:342 patients with a pre-PET differential diagnosis of PSP were referred to 18F-PI-2620 tau-PET in clinical routine. Of those, 200 patients (61.5
T2  - Alzheimer’s Association International Conference
CY  - 27 Jul 2025 - 31 Jul 2025, Toronto (Canada)
Y2  - 27 Jul 2025 - 31 Jul 2025
M2  - Toronto, Canada
KW  - Humans
KW  - Supranuclear Palsy, Progressive: diagnostic imaging
KW  - Supranuclear Palsy, Progressive: diagnosis
KW  - Supranuclear Palsy, Progressive: metabolism
KW  - Male
KW  - Female
KW  - tau Proteins: metabolism
KW  - Biomarkers: metabolism
KW  - Positron-Emission Tomography
KW  - Aged
KW  - Longitudinal Studies
KW  - Prospective Studies
KW  - Middle Aged
KW  - Disease Progression
KW  - tau Proteins (NLM Chemicals)
KW  - Biomarkers (NLM Chemicals)
LB  - PUB:(DE-HGF)1 ; PUB:(DE-HGF)16
DO  - DOI:10.1002/alz70856_102121
UR  - https://pub.dzne.de/record/283042
ER  -